Statements (55)
Predicate | Object |
---|---|
gptkbp:instanceOf |
monoclonal antibody
|
gptkbp:administrativeDivision |
once a month after initial loading dose
|
gptkbp:approves |
gptkb:FDA
|
gptkbp:brand |
Cosentyx
|
gptkbp:clinicalTrials |
Phase III
FUTURE 1 FUTURE 2 FUTURE 3 MEASURE 1 MEASURE 2 active ankylosing spondylitis active psoriatic arthritis non-radiographic axial spondyloarthritis MAXIMISE chronic plaque psoriasis |
gptkbp:contraindication |
inflammatory bowel disease
liver enzyme elevation active infections thrombocytopenia hypersensitivity to the drug neutropenia serious infections |
gptkbp:dosageForm |
solution for injection
|
gptkbp:drugInterdiction |
immunosuppressants
live vaccines other biologics |
gptkbp:endOfLife |
about 27 days
|
gptkbp:formulation |
auto-injector
pre-filled syringe |
gptkbp:hasPopulation |
adults
|
https://www.w3.org/2000/01/rdf-schema#label |
Secukinumab
|
gptkbp:is_monitored_by |
liver function tests
complete blood count signs of infection |
gptkbp:issuedBy |
subcutaneous injection
|
gptkbp:lastProduced |
2015
|
gptkbp:manufacturer |
Novartis
|
gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:Japan gptkb:United_States |
gptkbp:numberOfStudents |
metabolized by the reticuloendothelial system
|
gptkbp:patentExpiration |
2026
|
gptkbp:sideEffect |
fatigue
headache nausea injection site reactions upper respiratory infections |
gptkbp:storage |
refrigerated
|
gptkbp:targets |
IL-17A
|
gptkbp:triggerType |
neutralizes IL-17A
|
gptkbp:usedFor |
treatment of psoriasis
treatment of ankylosing spondylitis treatment of psoriatic arthritis |